The initial success of the copyright undeniably reshaped the medication landscape, but betting in companies heavily reliant on unbranded versions presents a challenging picture. While early profits were impressive, the end of patents and the rise of discounted alternatives have weakened the customer base. Therefore, a thorough analysis of ongoing r